Tags

Type your tag names separated by a space and hit enter

Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group.
Br J Dermatol. 1997 Jan; 136(1):89-93.BJ

Abstract

The efficacy, safety and tolerability of calcipotriol cream was compared with betamethasone 17-valerate cream in the treatment of plaque-type psoriasis in a multicentre double-blind, parallel group study. Patients with stable mild-to-moderate chronic disease were randomized to treatment with either calcipotriol, 50 micrograms/g, in a cream formulation (210 patients) or betamethasone 17-valerate cream, 1 mg/g (211 patients). After a wash-out period of 2 weeks, the treatment was applied twice daily, without occlusion, for 8 weeks or to complete clearing. The severity of psoriasis was assessed using the PASI at baseline and after 4 and 8 weeks treatment. The mean percentage reduction of PASI from baseline to end of treatment was 47.8% in the calcipotriol group and 45.4% in the betamethasone group. The reduction from baseline was highly significant in both groups, but the difference between the groups was not significant. There was a difference in the reduction in thickness of the lesions in favour of calcipotriol. The investigator's as well as the patient's overall assessment of treatment response at end of treatment showed no difference between the two treatment groups. Treatment-related adverse events were more frequent with calcipotriol than betamethasone. Lesional/perilesional irritation was reported in 16% and 9% (P = 0.03), and facial irritation in 10% and 0.5% (P < 0.001), respectively. No change was found in serum levels of calcium. Calcipotriol in a cream formulation was effective, safe, well-tolerated, and equal in effect to betamethasone valerate cream.

Authors+Show Affiliations

Department of Dermatology, Orebro Medical Center Hospital, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9039301

Citation

Molin, L, et al. "Comparative Efficacy of Calcipotriol (MC903) Cream and Betamethasone 17-valerate Cream in the Treatment of Chronic Plaque Psoriasis. a Randomized, Double-blind, Parallel Group Multicentre Study. Calcipotriol Study Group." The British Journal of Dermatology, vol. 136, no. 1, 1997, pp. 89-93.
Molin L, Cutler TP, Helander I, et al. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. Br J Dermatol. 1997;136(1):89-93.
Molin, L., Cutler, T. P., Helander, I., Nyfors, B., & Downes, N. (1997). Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. The British Journal of Dermatology, 136(1), 89-93.
Molin L, et al. Comparative Efficacy of Calcipotriol (MC903) Cream and Betamethasone 17-valerate Cream in the Treatment of Chronic Plaque Psoriasis. a Randomized, Double-blind, Parallel Group Multicentre Study. Calcipotriol Study Group. Br J Dermatol. 1997;136(1):89-93. PubMed PMID: 9039301.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. AU - Molin,L, AU - Cutler,T P, AU - Helander,I, AU - Nyfors,B, AU - Downes,N, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 89 EP - 93 JF - The British journal of dermatology JO - Br J Dermatol VL - 136 IS - 1 N2 - The efficacy, safety and tolerability of calcipotriol cream was compared with betamethasone 17-valerate cream in the treatment of plaque-type psoriasis in a multicentre double-blind, parallel group study. Patients with stable mild-to-moderate chronic disease were randomized to treatment with either calcipotriol, 50 micrograms/g, in a cream formulation (210 patients) or betamethasone 17-valerate cream, 1 mg/g (211 patients). After a wash-out period of 2 weeks, the treatment was applied twice daily, without occlusion, for 8 weeks or to complete clearing. The severity of psoriasis was assessed using the PASI at baseline and after 4 and 8 weeks treatment. The mean percentage reduction of PASI from baseline to end of treatment was 47.8% in the calcipotriol group and 45.4% in the betamethasone group. The reduction from baseline was highly significant in both groups, but the difference between the groups was not significant. There was a difference in the reduction in thickness of the lesions in favour of calcipotriol. The investigator's as well as the patient's overall assessment of treatment response at end of treatment showed no difference between the two treatment groups. Treatment-related adverse events were more frequent with calcipotriol than betamethasone. Lesional/perilesional irritation was reported in 16% and 9% (P = 0.03), and facial irritation in 10% and 0.5% (P < 0.001), respectively. No change was found in serum levels of calcium. Calcipotriol in a cream formulation was effective, safe, well-tolerated, and equal in effect to betamethasone valerate cream. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/9039301/Comparative_efficacy_of_calcipotriol__MC903__cream_and_betamethasone_17_valerate_cream_in_the_treatment_of_chronic_plaque_psoriasis__A_randomized_double_blind_parallel_group_multicentre_study__Calcipotriol_Study_Group_ DB - PRIME DP - Unbound Medicine ER -